<DOC>
	<DOCNO>NCT01344174</DOCNO>
	<brief_summary>This randomize , open label study evaluate efficacy safety glucocorticoid patient HBV associate pre-ACLF . Sponsor : Department infectious disease , Southwest Hospital . Indication : HBV associate acute-on-chronic pre-liver failure ( pre-ACLF-HBV ) . Objective : To evaluate efficacy safety glucocorticoid patient pre-ACLF-HBV . Trial Design : Randomized , open label study . Patients pre-ACLF-HBV randomize 1:1 One two group : A ) Dexamethasone 10mg intravenously injected po daily first 5 day , combination continue lamivudine 100mg po daily traditional supporting treatment 13 week . B ) Control group . Any glucocorticoid give patient . Continued lamivudine 100mg po daily traditional supporting treatment give 13 week . Number patient : Approximate number patient randomize : N=200 ( 100 patient group ) . Length study : Screening period : 3 day ; treatment period : 13 week . Duration study : 30 month first patient randomize , include recruitment period 26 month . Investigational treat regimen : Dexamethasone 10mg , iv , day 5 day . Concomitant Comparative regimen : Lamivudine 100mg po daily , traditional supporting treatment . Assessments Efficacy Primary endpoint : survival rate week 13 . Secondary endpoint : ①The level serum T-Bil ≤ 51.3µmol/L ; ②PTA ＞80 % . Safety : Adverse event , vital sign , laboratory test . Procedures ( summary ) : After sign informed consent meeting screen parameter , patient randomize one two treatment group describe trial design . After randomization patient see evaluation day 5,10,14,21,28,42,56,70,84,91 . Statistical analysis : Assume 1:1 randomization . The sample size calculate primary efficacy variable , survival rate . Assuming survival rate equal : 90 % group A 50 % group B . 100 patient group require yield 80 % chance detect difference two-tailed test employ 0.05 significance level . Every eligible subject assign randomization code receive one two treatment , accord sequence enrol .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Glucocorticoids Patients With Pre-ACLF-HBV</brief_title>
	<detailed_description>Synopsis Protocol Protocol number : preACLF2011 Title : A randomized , open label study evaluate efficacy safety glucocorticoid patient HBV associate pre-ACLF . Sponsor : Department infectious disease , Southwest Hospital . Indication : HBV associate acute-on-chronic pre-liver failure ( pre-ACLF-HBV ) . Objective : To evaluate efficacy safety glucocorticoid patient pre-ACLF-HBV . Trial Design : Randomized , open label study . Patients pre-ACLF-HBV randomize 1:1 one two group : A ) 10mg dexamethasone intravenously injected po daily first 5 day , combination continue lamivudine 100mg po daily traditional supporting treatment 13 week . B ) Any glucocorticoid give patient . Continued lamivudine 100mg po daily traditional supporting treatment give 13 week . Number patient : Approximate number patient randomize : N=200 ( 100 patient group ) Length study : Screening period : 3 day ; treatment period : 13 week . Duration study : 30 month first patient randomize , include recruitment period 26 month . Investigational treat regimen : Short-term glucocorticoid treatment ( 10mg dexamethasone , iv , day first 5 day ) . Concomitant comparative regimen treatment : Lamivudine 100mg po daily , traditional support treatment include : ①Transfusion magnesium glycyrrhizinate injection ( 200mg , 1/d ) reduce glutathione ( 1200mg , 1/d ) ; ②S-adenosyl-L- methionine ( 500 mg , intravenously , 2/d ) ; ③Transfusion human albumin ( 10 g , twice week ) fresh frozen plasma ( 200 ml , twice week ) ; ④Nutritional supplement prophylactic therapy various complication give . Assessments efficacy : Primary endpoint : survival rate week 13 . Secondary endpoint : ①The level serum T-Bil ≤51.3µmol/L ; ②PTA ＞80 % . Safety : Adverse event , vital sign , laboratory test . Procedures ( summary ) : After sign informed consent meeting screen parameter , patient randomize one two treatment group describe trial design . After randomization patient see evaluation day 5,10,14,21,28,42,56,70,84,91 . Statistical analysis Assume 1:1 randomization . The sample size calculate primary efficacy variable , survival rate . Assuming survival rate equal : 90 % group A 50 % group B . 100 patient group require yield 80 % chance detect difference two-tailed test employ 0.05 significance level . Every eligible subject assign randomization code receive one two treatment , accord sequence enrol .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Male female patient ≥18 ≤ 65 year age ; serum hepatitis B surface antigen ( HBsAg ) positive least 12 month ; serum HBV DNA ≥104copies/ml , receive antiviral treatment interferon NA within 12 month ; serum TBil≥171µmol/L ; PTA＞40 % ; serum ALT≥10×ULN two week &gt; 5×ULN initiation treatment . superinfection coinfection HAV , HCV , HDV , HEV , CMV , HIV , EBV ; liver diseases alcoholic liver disease , druginduced hepatitis , Wilson disease , autoimmune hepatitis ; ascites determine abdominal ultrasound scan ; gastrointestinal bleeding peptic ulcer oesophageal varix ; cirrhosis abdominal ultrasound scan ; bacterial fungal infection ; malignant jaundice induce obstructive hemolytic jaundice ; history diabetes cardiac disease hypertension nephrosis . Inability unwillingness provide inform consent abide requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Acute-on-chronic liver failure</keyword>
	<keyword>HBV</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Prognosis</keyword>
</DOC>